News — TAMPA, Fla. (Sept. 15, 2011) 鈥� For patients with ovarian cancer and their physicians, resistance to chemotherapy is a serious concern. However, researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance. They are hopeful that the discovery may lead to therapies that are tailored to individual patients with ovarian cancer; reversing resistance to chemotherapy and improving survival from the disease. 鈥淔ew clinical or biologic events affect survival for patients with ovarian cancer more than the way their tumors respond to chemotherapy,鈥� said Johnathan Lancaster, M.D., Ph.D., senior author on a study into chemotherapy resistance recently published in the journal Clinical Cancer Research (17:00, 2011). 鈥淲e identified a pathway called the 鈥楤CL2 antagonist of cell death,鈥� or BAD, and determined that the activity of the BAD pathway may have more influence on survival than the volume of residual disease after primary surgery.鈥� According to Lancaster and colleagues, the discovery of BAD opens the door to using the pathway as a biomarker to identify patients with the highest-risk ovarian cancer, which are genetically programmed to be resistant to chemotherapy; enabling physicians to identify patients who might benefit from drugs that inhibit the BAD pathway such that chemo-resistance is reversed. 鈥淭argeted therapies that increase a tumor鈥檚 sensitivity to chemotherapy offer the potential to improve patient survival,鈥� explained Lancaster, chair of the Department of Women鈥檚 Oncology and director of the Center for Women鈥檚 Oncology at Moffitt. By treating ovarian cancer cells in a test tube (in vitro) with a chemotherapy drug and observing which genetic pathways became most active, the researchers identified the BAD pathway. To further analyze the activity of the BAD pathway and levels of the BAD protein, the researchers examined tumor specimens and genomic information from almost 300 patients with advanced ovarian cancer. A 47-gene BAD pathway signature was developed and was found to be associated with survival. Subsequent in vitro tests on ovarian cancer cells suggest that it may be possible to inhibit the BAD pathway and reverse resistance to chemotherapy. 鈥淚ntriguingly, patients who had lots of cancer remaining at the conclusion of their surgery but whose tumors had low levels of pBAD protein, had better survival than patients with very little cancer remaining following surgery, but who had high levels of pBAD protein,鈥� said Lancaster. 鈥淎lthough our data highlights the importance of this newly identified pathway, not all cell line samples showed associations between chemotherapy resistance and BAD pathway genes. There are likely many other pathways and processes contributing to chemotherapy resistance.鈥� The researchers concluded that although more research is necessary, BAD pathway-based biomarkers could open the door to personalized treatment for ovarian cancer by placing women in high-risk and low-risk groups based on their genetic profile for the BAD pathway and protein. Treatments could be selected for each patient according to the status of their BAD pathway.
About Moffitt Cancer CenterLocated in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center 鈥� a designation that recognizes Moffitt鈥檚 excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia, one in Pennsylvania and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country鈥檚 leading cancer centers, and is listed in U.S. 麻豆传媒 & World Report as one of 鈥淎merica鈥檚 Best Hospitals鈥� for cancer. Moffitt marks a very important anniversary in 2011 鈥� 25 years committed to one mission: to contribute to the prevention and cure of cancer.
RSS